Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Hadassah Medical Center: Barak Vivian

Last updated June 2021 - Hadassah Medical Center

List of Publications

(1) Meirovitz A, Gross M, Leibovici V, Sheva K, Popovzer A, Barak V. Clinical applicability of the proliferation marker thymidine kinase 1 in head and neck cancer patients. Anticancer Res 2021;41(2):1083-1087.

(2) Barak V, Itzkovich D, Einarsson R, Gofrit O, Pode D. Non-invasive detection of bladder cancer by UBC rapid test, ultrasonography and cytology. Anticancer Res 2020;40(7):3967-3972.

(3) Nicolini A, Barak V, Biava P, Ferrari P, Rossi G, Carpi A. The use of immunotherapy to treat metastatic breast cancer. Curr Med Chem 2019;26(6):941-962.

(4) Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, et al. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clin Chem Lab Med 2018;56(11):1945-1953.

(5) Dahan S, Bragazzi NL, Yogev A, Bar-Gad M, Barak V, Amital H, et al. The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia. Psychiatry Res 2018;268:467-472.

(6) Nicolini A, Carpi A, Ferrari P, Morganti R, Mazzotti V, Barak V, et al. An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manage Res 2018;10:6879-6886.

(7) Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, et al. Validation of new cancer biomarkers: The official position of the European Group on Tumor Markers. Biochim Clin 2017;41(1):102-113.

(8) Gross M, Meirovich A, Rachmut J, Kalichman I, Peretz T, Eliashar R, et al. The diagnostic and prognostic value of sIL-2R as an immune biomarker in head and neck cancers. Anticancer Res 2016;36(8):4347-4352.

(9) Barak V, Leibovici V, Peretz T, Kalichman I, Lotem M, Merims S. Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. Anticancer Res 2015;35(12):6755-6760.

(10) Landesberg G, Levin PD, Gilon D, Goodman S, Georgieva M, Weissman C, et al. Myocardial dysfunction in severe sepsis and septic shock: No correlation with inflammatory cytokines in real-life clinical setting. Chest 2015;148(1):93-102.

(11) Barak V, Pe'er J, Kalickman I, Frenkel S. Erratum: VEGF as a Biomarker for Metastatic Uveal Melanoma in Humans (Current Eye Research (2011) 36 (386-390)). Curr Eye Res 2015;40(8):862.

(12) Karlikova M, Topolcan O, Wolfe OTJ, Barak V, Zima T. Optimal Use of Biomarkers in Oncology. BioMed Res Int 2015;2015.

(13) Gatt ME, Goldschmidt N, Kalichman I, Friedman M, Arronson AC, Barak V. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation. Anticancer Res 2015;35(5):3019-3026.

(14) Barak V, Meirovitz A, Leibovici V, Rachmut J, Peretz T, Eliashar R, et al. The diagnostic and prognostic value of tumor markers (CEA, SCC, CYFRA 21-1, TPS) in head and neck cancer patients. Anticancer Res 2015;35(10):5519-5524.

(15) Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, et al. Validation of new cancer biomarkers: A position statement from the european group on tumor markers. Clin Chem 2015;61(6):809-820.

(16) Czerninski R, Basile JR, Kartin-Gabay T, Laviv A, Barak V. Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: A pilot study. Oral Dis 2014;20(5):477-481.

(17) Arnson Y, Itzhaky D, Mosseri M, Barak V, Tzur B, Agmon-Levin N, et al. Vitamin D inflammatory cytokines and coronary events: A comprehensive review. Clin Rev Allergy Immunol 2013;45(2):236-247.

(18) Frenkel S, Zloto O, Pe'er J, Barak V. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans. Invest Ophthalmol Vis Sci 2013;54(1):490-493.

(19) Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, et al. Design of tumor biomarker-monitoring trials: A proposal by the European Group on Tumor Markers. Clin Chem 2013;59(1):52-59.

(20) Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, et al. Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy 2J/dy 2J mouse. Ann Neurol 2012;71(5):699-708.

(21) Oberbaum M, Spira RM, Lukasiewicz E, Armon Y, Samuels N, Singer SR, et al. Effect of traumeel S on cytokine profile in a cecal ligation and puncture (CLP) sepsis model in rats. J Altern Complement Med 2011;17(10):909-913.

(22) Barak V, Pe'er J, Kalickman I, Frenkel S. VEGF as a biomarker for metastatic uveal melanoma in humans. Curr Eye Res 2011;36(4):386-390.

(23) Beloosesky Y, Weiss A, Hershkovitz A, Hendel D, Barak V. Serum transforming growth factor beta-1 post hip fracture repair in elderly patients. Cytokine 2011;54(1):56-60.

(24) Nicolini A, Conte M, Rossi G, Ferrari P, Duffy M, Barak V, et al. Additional 5-FU-LV significantly increases survival in gastrointestinal cancer. Front Biosci Elite 2011;3 E(4):1475-1482.

(25) Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Pe'er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (Part 1). Anticancer Res 2011;31(1):345-349.

(26) Hendler K, Pe'er J, Kaiserman I, Baruch R, Kalickman I, Barak V, et al. Trends in liver function tests: A comparison with serum tumor markers in metastatic uveal melanoma (Part 2). Anticancer Res 2011;31(1):351-357.

(27) Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011;70(1):145-150.

(28) Arad I, Bar-Oz B, Ergaz Z, Nir A, Barak V. Interleukin-6 and n-terminal pro-brain natriuretic peptide cord blood levels in premature infants: Correlations with perinatal variables. Isr Med Assoc J 2010;12(7):419-423.

(29) Amital H, Szekanecz Z, Szücs G, Dankó K, Nagy E, Csépány T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: Is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010;69(6):1155-1157.

(30) Dror R, Lederman M, Umezawa K, Barak V, Pe'er J, Chowers I. Characterizing the involvement of the nuclear factorkappa b (NFκB) transcription factor in uveal melanoma. Invest Ophthalmol Vis Sci 2010;51(4):1811-1816.

(31) Meirovitz A, Kuten M, Billan S, Abdah-Bortnyak R, Sharon A, Peretz T, et al. Cytokines levels, Severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer - a prospective pilot study. Radiat Oncol 2010;5(1).

(32) Vaisman N, Press J, Leibovitz E, Boehm G, Barak V. Short-term effect of prebiotics administration on stool characteristics and serum cytokines dynamics in very young children with acute diarrhea. Nutr 2010;2(7):683-692.

(33) Goldschmidt N, Verber A, Neuman T, Kalikhman I, Barak V. Vascular endothelial growth factors (VEGF) as a major parameter for diagnosis and follow up of a patient with POEMS syndrome. J Neurol Sci 2010;27(3):348-352.

(34) Barak V, Holdenrieder S, Nisman B, Stieber P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomarkers 2009;6(3-4):191-196.

(35) Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res 2009;29(11):4827-4832.

(36) Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I, et al. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 2009;33(3-4):178-182.

(37) Nisman B, Yutkin V, Peretz T, Shapiro A, Barak V, Pode D. The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: A pilot study. Anticancer Res 2009;29(10):4281-4285.

(38) Waknine-Grinberg JH, El-On J, Barak V, Barenholz Y, Golenser J. The immunomodulatory effect of Sambucol on leishmanial and malarial infections. Planta Med 2009;75(6):581-586.

(39) Mashiah J, Brenner S, Pessach Y, Barak V, Schachter J. Differences in cytokine levels in melanoma patients with and without redness (Brenner sign). Anticancer Res 2009;29(5):1793-1796.

(40) Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E. Recombinant luteinizing hormone induces increased production of ovarian follicular adiponectin in vivo: implications for enhanced insulin sensitivity. Fertil Steril 2009;91(5):1837-1841.

(41) Rott D, Leibowitz D, Finci-Yeheskel Z, Barak V, Chajek-Shaul T, Weiss T, et al. The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction. Cardiology 2008;112(1):56-59.

(42) Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis. Fertil Steril 2008;89(4):922-926.

(43) Nisman B, Biran H, Heching N, Barak V, Ramu N, Nemirovsky I, et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: Association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 2008;98(1):77-79.

(44) Molina R, Barak V, Van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer - European Group on Tumor Markers (EGTM) recommendations. Intern Med Clin Lab 2007;15-16:29-31.

(45) Barak V, Frenkel S, Valyi-Nagy K, Leach L, Apushkin MA, Lin AY, et al. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker. Invest Ophthalmol Vis Sci 2007;48(10):4399-4402.

(46) Portugal M, Barak V, Ginsburg I, Kohen R. Interplay among oxidants, antioxidants, and cytokines in skin disorders: Present status and future considerations. Biomed Pharmacother 2007;61(7):412-422.

(47) Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res 2007;27(4 A):1897-1900.

(48) Folberg R, Leach L, Valyi-Nagy K, Lin AY, Apushkin MA, Ai Z, et al. Modeling the behavior of uveal melanoma in the liver. Invest Ophthalmol Vis Sci 2007;48(7):2967-2974.

(49) Handzel ZT, Barak V, Altman Y, Bibi H, Lidgi M, Iancovici-Kidon M, et al. Increased Th1 and Th2 type cytokine production in patients with active tuberculosis. Isr Med Assoc J 2007;9(6):479-483.

(50) Amital H, Barak V, Winkler RE, Rubinow A. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Ann New York Acad Sci 2007;1110:649-660.

(51) Beloosesky Y, Hendel D, Weiss A, Hershkovitz A, Grinblat J, Pirotsky A, et al. Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. J Gerontol Ser A Biol Sci Med Sci 2007;62(4):420-426.

(52) Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann New York Acad Sci 2007;1109:385-400.

(53) Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, et al. Osteopontin expression and serum levels in metastatic uveal melanoma: A pilot study. Invest Ophthalmol Vis Sci 2006;47(3):802-806.

(54) Vaisman N, Zaruk Y, Shirazi I, Kaysar N, Barak V. The effect of fish oil supplementation on cytokine production in children. Eur Cytokine Netw 2005;16(3):194-198.

(55) Nisman B, Heching N, Biran H, Barak V, Peretz T. The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumor Biol 2005;27(1):8-16.

(56) Molina R, Barak V, Van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer - European group on tumor markers recommendations. Tumor Biol 2005;26(6):281-293.

(57) Reichert F, Barak V, Tarshis M, Prindull G, Tarshis E, Ben-Ishay Z. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies. Eur J Haematol 2005;75(1):41-46.

(58) Raveh D, Shemesh O, Ashkenazi YJ, Winkler R, Barak V. Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome. Pediatr Nephrol 2004;19(11):1281-1284.

(59) Barak V, Elchalal U, Edelstein M, Kalickman I, Lewin A, Abramov Y. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril 2004;82(2):415-420.

(60) Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37(7):529-540.

(61) Barak V, Kalickman I, Halperin T, Birkenfeld S, Ginsburg I. PADMA-28, a Tibetan herbal preparation is an inhibitor of inflammatory cytokine production. Eur Cytokine Netw 2004;15(3):203-209.

(62) Vaisman N, Hahn T, Karov Y, Sigler E, Barak Y, Barak V. Changes in cytokine production and impaired hematopoiesis in patients with anorexia nervosa: The effect of refeeding. Cytokine 2004;26(6):255-261.

(63) Abramov Y, Ezra Y, Elchalal U, Ben-Shachar I, Fasouliotis SJ, Barak V. Markedly elevated levels of inflammatory cytokines in maternal serum and peritoneal washing during arrested labor. Acta Obstet Gynecol Scand 2004;83(4):358-363.

(64) Shapira J, Berenstein-Ajzman G, Engelhard D, Cahan S, Kalickman I, Barak V. Cytokine levels in gingival crevicular fluid of erupting primary teeth correlated with systemic disturbances accompanying teething. Pediatr Dent 2003;25(5):441-448.

(65) Vaisman N, Leibovitz E, Dagan R, Barak V. The involvement of IL-6 and IL-8 in acute invasive gastroenteritis of children. Cytokine 2003;22(6):194-197.

(66) Nisman B, Barak V, Hubert A, Kaduri L, Lyass O, Baras M, et al. Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy. Anticancer Res 2003;23(2 C):1939-1942.

(67) Zahalka MA, Barak V, Traub L, Moroz C. PLIF induces IL-10 production in monocytes: a calmodulin-p38 mitogen-activated protein kinase-dependent pathway. FASEB J 2003;17(8):955-957.

(68) Scheinowitz M, Heled Y, Chouraqui P, Vered Z, Hayardeni Y, Kotlyar A, et al. Dalteparin sodium (Fragmin®). Administration following acute infarction does not affect myocardial perfusion and function in swine. Cardiovasc Drugs Ther 2002;16(4):303-309.

(69) Barak V, Birkenfeld S, Halperin T, Kalickman I. The effect of herbal remedies on the production of human inflammatory and anti-inflammatory cytokines. Isr Med Assoc J 2002;4(11 SUPPL.):919-922.

(70) Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002;94(11):2914-2922.

(71) Abramov Y, Anteby SO, Fasouliotis SJ, Barak V. The role of inflammatory cytokines in Meigs' syndrome. Obstet Gynecol 2002;99(5 SUPPL. 1):917-919.

(72) Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, Eshhar Z, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 2002;51(2):73-83.

(73) Barak V, Nisman B, Hubert A, Lyass O, Peretz T. Cytokeratins - Clinical utility in breast cancer. J Clin Ligand Assay 2002;25(1):40-42.

(74) Weiss L, Barak V, Zeira M, Abdul-Hai A, Raibstein I, Reich S, et al. Cytokine production in linomide-treated NOD mice and the potential role of a Th1/Th2 shift on autoimmune and anti-inflammatory processes. Cytokine 2002;19(2):85-93.

(75) Abrahamov D, Erez E, Tamariz M, Dagan O, Pearl E, Abrahamov Y, et al. Plasma vascular endothelial growth factor level is a predictor of the severity of postoperative capillary leak syndrome in neonates undergoing cardiopulmonary bypass. Pediatr Surg Int 2002;18(1):54-59.

(76) Zecchina G, Novick D, Rubinstein M, Barak V, Dinarello C, Nagler A. Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. J Hematother Stem Cell Res 2001;10(6):769-776.

(77) Abramov Y, Schenker JG, Lewin A, Kafka I, Jaffe H, Barak V. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndome. Fertil Steril 2001;76(1):51-57.

(78) Barak V, Halperin T, Kalickman I. The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines. Eur Cytokine Netw 2001;12(2):290-296.

(79) Ben-Ishay Z, Barak V. Bone marrow stromal dysfunction in mice administered cytosine arabinoside. Eur J Haematol 2001;66(4):230-237.

(80) Condiotti R, Zakai YB, Barak V, Nagler A. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. Exp Hematol 2001;29(1):104-113.

(81) Abramov Y, Anteby SO, Fasouliotis SJ, Barak V. Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome. Am J Obstet Gynecol 2001;184(3):354-355.

(82) Abramov Y, Anteby SO, Fatum M, Fasouliotis SJ, Barak V. The kinetics of leptin in Meigs' syndrome. Gynecol Oncol 2001;83(2):316-318.

(83) Nisman B, Heching N, Barak V. Serum tumor markers in resectable and nonresectable non-small cell lung cancer. J Tumor Marker Oncol 2000;15(3):195-206.

(84) Barak V, Nisman B, Hubert A, Lyass O, Kaduri L, Peretz T. Prognostic efficacy of TPS in breast cancer. J Tumor Marker Oncol 2000;15(3):171-176.

(85) Nagler RM, Barak V, Nagler A. Short term systemic effects of head and neck irradiation. Anticancer Res 2000;20(3 A):1865-1870.

(86) Abramov D, Erez E, Dagan O, Abramov Y, Pearl E, Veena G, et al. Increased levels of basic fibroblast growth factor are found in the cross-clamped heart during cardiopulmonary bypass. Can J Cardiol 2000;16(3):313-318.

(87) Houri-Haddad Y, Soskolne WA, Halabi A, Barak V, Shapira L. Repeat bacterial challenge in a subcutaneous chamber model results in augmented tumour necrosis factor-α and interferon-γ response, and suppression of interleukin-10. Immunology 2000;99(2):215-220.

(88) Kori M, Barak V, Leibovitz E, Altman Y, Eliraz A, Handzel ZT. Specific in vitro proliferative immune responses and lymphokine production in Ethiopian children with and without tuberculosis. Infection 2000;28(1):42-45.

(89) Israel ZH, Lossos A, Barak V, Soffer D, Siegal T. Multifocal demyelinative leukoencephalopathy associated with 5- fluorouracil and levamisole. Acta Oncol 2000;39(1):117-120.

(90) Aizman I, Many A, Rosenthal E, Schiby G, Goldberg I, Barak V, et al. Neoplastic cell activation and proliferative response to CD40-ligand characterize recurrent leukemic bouts in an unusual case of low grade lymphoma. Leuk Lymphoma 2000;36(5-6):613-623.

(91) Pizov R, Weiss YG, Oppenheim-Eden A, Glickman H, Goodman S, Koganov Y, et al. High oxygen concentration exacerbates cardiopulmonary bypass-induced lung injury. J Cardiothorac Vasc Anesth 2000;14(5):519-523.

(92) Einarsson R, Barak V. TPS(TM): A cytokeratin serum tumor marker for effective of cancer patients with focus on breast cancer. J Clin Ligand Assay 1999;22(4):348-351.

(93) Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T, et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999;19(4 C):3549-3552.

(94) Levine J, Barak Y, Chengappa KRN, Rapoport A, Antelman SM, Barak V. Low CSF soluble interleukin 2 receptor levels in acute depression. J Neural Transm 1999;106(9-10):1011-1015.

(95) Levine J, Barak Y, Chengappa KNR, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999;40(4):171-176.

(96) Tomer Y, Barak V, Gilburd B, Shoenfeld Y. Cytokines in experimental autoimmune vasculitis: Evidence for a Th2 type response. Clin Exp Rheumatol 1999;17(5):521-526.

(97) Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, et al. Cytokines in Gaucher's disease. Eur Cytokine Netw 1999;10(2):205-210.

(98) Krause I, Blank M, Levi Y, Koike T, Barak V, Shoenfeld Y. Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol 1999;117(1):190-197.

(99) Blank M, Krause I, Goldkorn T, Praprotnik S, Livneh A, Langevitz P, et al. Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels. Arthritis Rheum 1999;42(7):1421-1432.

(100) Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M, et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1α expression. Cancer Res 1999;59(5):1029-1035.

(101) Geva E, Amit A, Lessing JB, Lerner-Geva L, Daniel Y, Yovel I, et al. Follicular fluid levels of vascular endothelial growth factor: Are they predictive markers for ovarian hyperstimulation syndrome? J Reprod Med Obstet Gynecol 1999;44(2):91-96.

(102) Hirshberg B, Kramer MR, Lotem M, Barak V, Shustin L, Amir G, et al. Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma. Am J Hematol 1999;60(2):143-147.

(103) Barak V, Nisman B, Polliack A. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 1999;62(2):71-75.

(104) Rosen G, Sela MN, Naor R, Halabi A, Barak V, Shapira L. Activation of murine macrophages by lipoprotein and lipooligosaccharide of Treponema denticola. Infect Immun 1999;67(3):1180-1186.

(105) Nisman B, Lafair J, Lyass O, Dranitzki-Elhalel M, Barak V. Serum Levels of CEA, SCC, TPS and CYFRA 21-1 in Hemodialysis Patients. J Tumor Marker Oncol 1998;13(2):87-93.

(106) Nisman B, Lafair J, Lyass O, Dranitzki-Elhalel M, Barak V. Serum Levels of CEA, SCC, TPS and CYFRA 21-1 in Hemodialysis Patients. J Tumor Marker Oncol 1998;13(1):33-39.

(107) Blank M, George J, Barak V, Tincani A, Koike T, Shoenfeld Y. Oral tolerance to low dose β2-glycoprotein I: Immunomodulation of experimental antiphospholipid syndrome. J Immunol 1998;161(10):5303-5312.

(108) Amital H, Levi Y, Blank M, Barak V, Langevitz P, Afek A, et al. Immunomodulation of murine experimental SLE-like disease by interferon-γ. Lupus 1998;7(7):445-454.

(109) Nisman B, Barak V, Heching N, Kramer M, Reinus C, Lafair J. Cytokeratin markers in malignant pleural mesothelioma. Cancer Detect Prev 1998;22(5):416-421.

(110) Nagler A, Bishara A, Brautbar C, Barak V. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation. Cytokines Cell Mol Ther 1998;4(3):161-167.

(111) Barak V, Nisman B, Polliack A, Vannier E, Dinarello CA. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Eur Cytokine Netw 1998;9(1):33-39.

(112) Bishara A, Malka R, Brautbar C, Barak V, Cohen I, Kedar E. Cytokine production in human mixed leukocyte reactions performed in serum-free media. J Immunol Methods 1998;215(1-2):187-190.

(113) Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: Does the combined use of cytokeratin markers give any additional information? Cancer 1998;82(10):1850-1859.

(114) Blank M, George J, Fishman P, Levy Y, Toder V, Savion S, et al. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony- stimulating factor expression. Arthritis Rheum 1998;41(2):224-232.

(115) Deutsch E, Nisman B, Kaufman M, Barak V. Cytokine evaluation in throat infections. Ann Otol Rhinol Laryngol 1998;107(8):713-716.

(116) Shapira L, Barak V, Soskolne WA, Halabi A, Stabholz A. Effects of tetracyclines on the pathologic activity of endotoxin: in vitro and in vivo studies. Adv Dent Res 1998;12(2):119-122.

(117) Barak V, Schwartz A, Kalickman I, Nisman B, Gurman G, Shoenfeld Y. Prevalence of hypophosphatemia in sepsis and infection: The role of cytokines. Am J Med 1998;104(1):40-47.

(118) Barak V, Kalickman I, Nisman B, Farbstein H, Fridlender ZG, Baider L, et al. Changes in cytokine production of breast cancer patients treated with interferons. Cytokine 1998;10(12):977-983.

(119) Van Dalen A, Barak V, Cremaschi A, Gion M, Molina R, Namer M, et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int J Biol Markers 1998;13(1):10-15.

(120) Shapira L, Soskolne A, Halabi A, Barak V, Stabholz A. Induction of tumor necrosis factor α and interleukin-1β in subcutaneously implanted chamber by lipopolysaccharide. Innate Immun 1997;4(5):325-329.

(121) Barak V, Nisman B, Roisman I, Hubert A, Farbstein H, Baider L, et al. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J Tumor Marker Oncol 1997;12(4):17-25.

(122) Toren A, Barak V, Novick D, Nagler A. Soluble interferon-γ receptor and interferon-γ in patients undergoing allogeneic bone marrow transplantation for hematological malignancies. Cytokines Cell Mol Ther 1997;3(3):153-158.

(123) Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, et al. Serum basic fibroblast growth factor levels in patients with ischemic heart disease. Int J Cardiol 1997;59(2):133-138.

(124) Levi-Schaffer F, Segal V, Barak V, Rubinchik E, Nagler A. Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human chronic graft-vs.-host disease. Exp Hematol 1997;25(3):238-245.

(125) BenEzra D, Maftzir G, Barak V. Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behcet disease. Am J Ophthalmol 1997;123(5):593-598.

(126) Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997;67(2):261-265.

(127) Levy Y, George J, Barak V, Shoenfeld Y. Early detection of recurrent mono-metastases of breast cancer to endocrine tissues by following CEA levels. Oncol Rep 1997;4(3):623-624.

(128) Shapira L, Soskolne A, Halabi A, Barak V, Stabholz A. Induction of tumor necrosis factor α and interleukin-1β in subcutaneously implanted chamber by lipopolysaccharide. J Endotoxin Res 1997;4(5):325-329.

(129) Gilad R, Lampl Y, Eshel Y, Barak V, Sarova-Pinhas I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol 1997;36(2):190-193.

(130) Peretz T, Kaplan-Denour A, Baider L, Hubert A, Stephanos S, Barak V. Combination of interferon and tamoxifen for patients with advanced breast cancer and negative oestrogen receptors. BREAST 1997;6(4):190-193.

(131) Merimsky O, Hareuveni M, Barak V, Sperber F, Eshkol Z, Chaitchik S. Elevated breast cancer serum markers in otherwise healthy women. Oncol Rep 1997;4(4):829-832.

(132) Shapira L, Houri Y, Barak V, Soskolne WA, Halabi A, Stabholz A. Tetracycline inhibits Porphyromonas gingivalis lipopolysaccharide-induced lesions in vivo and TNfα processing in vitro. J Periodontal Res 1997;32(1 PART 2):183-188.

(133) Zandman-Goddard G, George J, Blank M, Levy Y, Yanai P, Halperin T, et al. The effects of early and late administration of M-20 derived interleukin-1 inhibitor on experimental systemic lupus erythematosus. Immunol Lett 1996;53(2-3):77-82.

(134) Shimonovitz S, Hurwitz A, Barak V, Dushnik M, Adashi EY, Anteby E, et al. Cytokine-mediated regulation of type IV collagenase expression and production in human trophoblast cells. J Clin Endocrinol Metab 1996;81(8):3091-3096.

(135) Levi-Schaffer F, Barkans J, Newman TM, Ying S, Wakelin M, Hohenstein R, et al. Identification of interleukin-2 in human peripheral blood eosinophils. Immunology 1996;87(1):155-161.

(136) Nagler A, Shur I, Barak V, Fabian I. Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation. Leuk Res 1996;20(8):637-643.

(137) Condiotti R, Slavin S, Barak V, Nagler A. The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. Leuk Res 1996;20(1):57-63.

(138) Yakovlev E, Kalichman I, Pisanti S, Shoshan S, Barak V. Levels of cytokines and collagen type I and type III as a function of age in human gingivitis. J Periodontol 1996;67(8):788-793.

(139) Shapira L, Aubrey Soskolne W, Houri Y, Barak V, Halabi A, Stabholz A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: Correlation with inhibition of cytokine secretion. Infect Immun 1996;64(3):825-828.

(140) Shapira L, Houri Y, Barak V, Halabi A, Soskolne WA, Stabholz A. Human monocyte response to cementum extracts from periodontally diseased teeth: Effect of conditioning with tetracycline. J Periodontol 1996;67(7):682-687.

(141) Vaisman N, Barak Y, Hahn T, Karov Y, Malach L, Barak V. Defective in vitro granulopoiesis in patients with anorexia nervosa. Pediatr Res 1996;40(1):108-111.

(142) Abramov Y, Schenker JG, Lewin A, Friedler S, Nisman B, Barak V. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 1996;11(7):1381-1386.

(143) Deutsch VR, Eldor A, Olson T, Barak V, Pick M, Nagler A. Stem cell factor (SCF) synergizes with megakaryocyte colony stimulating activity in post-irradiated aplastic plasma in stimulating human megakaryocytopoiesis. Med Oncol 1996;13(1):31-42.

(144) Hasdai D, Scheinowitz M, Leibovitz E, Sclarovsky S, Eldar M, Barak V. Increased serum concentrations of interleukin-1β in patients with coronary artery disease. Heart 1996;76(1):24-28.

(145) Revel A, Barak V, Lavy Y, Anteby E, Abramov Y, Schenker JJ, et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril 1996;66(1):66-71.

(146) Van Dalen A, Heering KJ, Barak V, Peretz T, Cremaschit A, Geroni P, et al. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes. BREAST 1996;5(2):82-88.

(147) Leibovici L, Evron R, Axelrod O, Westerman M, Shalit M, Barak V, et al. Imbalance of immune responses in patients with chronic and widespread fungal skin infection. Clin Exp Dermatol 1995;20(5):390-394.

(148) Nagler A, Or R, Nisman B, Kalickman I, Slavin S, Barak V. Elevated inflammatory cytokine levels in bone marrow graft rejection. Transplantation 1995;60(9):943-948.

(149) Barak V, Roisman I, Kaufman B. Utility of Ca 19-9 tumor marker in pancreatic carcinoma. Harefuah 1995;129(5-6):217-219.

(150) Wieder R, Barak V, Ben-Ishay Z. High-Efficiency Retroviral Gene Transfer into Murine High-Proliferative-Potential Cells Cycle-Activated by Cytosine Arabinoside. Hum Gene Ther 1995;6(7):865-871.

(151) Geva E, Gottesman G, Lemer-Geva L, Lang R, Pomeranz M, Barak V, et al. Secondary amenorrhoea due to persistent corpus luteum in brucellosis. Lancet 1995;345(8943):201.

(152) Barak V. Soluble cytokine receptors in disease. Isr J Med Sci 1995;31(9):565-571.

(153) Barak V. Cytokines and soluble cytokine receptors in Behcet's disease. Isr J Med Sci 1995;31(6):374-375.

(154) Barak V, Schaffer FL, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma 1995;17(1-2):169-173.

(155) Edelmann DZ, Peretz T, Barak V, Anteby SO. Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995;5(6):443-448.

(156) Barak V, Nisman B, Roisman I, Barak Y, Levine J. Changes in interleukin-1 β and soluble interleukin-2 receptor levels in csf and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 1995;6(1):61-70.

(157) Pode D, Shapiro A, Lebensart P, Meretyk S, Katz G, Barak V. Screening for prostate cancer. Isr J Med Sci 1995;31(2-3):125-128.

(158) Abramov Y, Galun E, Granat M, Barak V, Abramov D, Plotkin V, et al. Postpartum systemic capillary leak syndrome: a possible etiology. Acta Obstet Gynecol Scand 1995;74(5):395-398.

(159) Dann EJ, Gillis S, Rachmilewitz EA, Barak V, Cass Y, Ruchlemer R, et al. Hairy cell leukemia: Results of 2-chlorodeoxyadenosine therapy in Jerusalem. Leuk Lymphoma 1994;14(SUPPL. 1):127-131.

(160) Barak V, Ben-Ishay Z. Cytokine and growth factor gene expression by bone marrow stroma of mice with damaged hematopoiesis and during regeneration. Leuk Res 1994;18(10):733-739.

(161) Engelhard D, Singer R, Nagler A, Barak V. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after t-lymphocyte depleted bone marrow transplantation for hematological neoplasias. Leuk Lymphoma 1994;12(3-4):273-280.

(162) Nagler A, Ackerstein A, Barak V, Slavin S. Treatment of Chronic Myelogenous Leukemia with Recombinant Human Interleukin-2 and Interferon-α2a. J Hematother 1994;3(1):75-82.

(163) Shapira L, Soskolne WA, Sela MN, Offenbacher S, Barak V. The secretion of PGE2, IL-1 beta, IL-6, and TNF alpha by adherent mononuclear cells from early onset periodontitis patients. J Periodontol 1994;65(2):139-146.

(164) Fibach E, Rigel M, Peled T, Treves AJ, Barak V. The effect of human myelomonocytic leukemic cell line (m20) derived IL-1 inhibitor on human erythroid cell development. Leuk Lymphoma 1994;15(3-4):327-332.

(165) Shimonovitz S, Barak V, Zacut D, Ever-hadani P, Chetrit AB, Ron M. High concentration of soluble interleukin-2 receptors in ejaculate with low sperm motility. Hum Reprod 1994;9(4):653-655.

(166) Hahn T, Shulman LM, Ben-Hur H, Karov Y, Barak V, Handgretinger R, et al. Differential responses of fetal, neonatal, and adult myelopoietic progenitors to interferon and tumor necrosis factor. Exp Hematol 1994;22(2):114-121.

(167) Barak V, Nisman B, Dann EJ, Kalickman I, Ruchlemer R, Bennett MA, et al. Serum interleukin 1β levels as a marker in hairy cell leukemia: Correlation with disease status and sIL-2R levels. Leuk Lymphoma 1994;14(SUPPL. 1):33-39.

(168) Shapira L, Smidt A, Van Dyke TE, Barak V, Soskolne AW, Brautbar C, et al. Sequential manifestation of different forms of early-onset periodontitis. A case report. J Periodontol 1994;65(6):631-635.

(169) Manetti R, Barak V, Piccinni M-, Sampognaro S, Parronchi P, Maggi E, et al. Interleukin-1 favours the in vitro development of type 2 T helper (Th2) human T-cell clones. Res Immunol 1994;145(2):93-100.

(170) Barak V, Peritt D, Yanai P, Halperin T, Treves AJ. In vivo anti inflammatory effects of the M20 IL-1 Inhibitor: I. Effects on acute inflammatory parameters. Biotherapy 1993;6(4):263-270.

(171) Barak V, Gorodetsky R, Weidenfeld J, Peritt D, Yanai P, Halperin T, et al. In vivo anti-inflammatory effects of the M20 IL-1 Inhibitor: II. Effects on serum reactants. Biotherapy 1993;6(4):271-277.

(172) Shapira L, Takashiba S, Kalmar JR, Van Dyke TE, Barak V, Aubrey Soskolne W. Rapid fluorometric quantificaition of monocyte attachment in tissue culture wells. J Immunol Methods 1993;165(1):93-98.

(173) BenEzra D, Maftzir G, Kalichman I, Barak V. Serum levels of interleukin-2 receptor in ocular Behcet's disease. Am J Ophthalmol 1993;115(1):26-30.

(174) Putterman C, Barak V, Caraco Y, Neuman T, Shalit M. Episodic angioedema with eosinophilia: A case associated with T cell activation and cytokine production. Ann Allergy 1993;70(3):243-248.

(175) Barak V, Peritt D, Flechner I, Sherman Y, Okon E, Yanai P, et al. The M20 IL-1 inhibitor prevents onset of adjuvant arthritis. Biotherapy 1992;4(4):317-323.

(176) Peritt D, Flechner I, Yanai P, Okunev E, Halperin T, Treves AJ, et al. The M20 IL-1 inhibitor. II. Biological characterization. J Immunol Methods 1992;155(2):167-174.

(177) Peritt D, Flechner I, Okunev E, Yanai P, Halperin T, Treves AJ, et al. The M20 IL-1 inhibitor. I. Purification by preparative isoelectric focusing in free solution. J Immunol Methods 1992;155(2):159-165.

(178) Rotshenker S, Aamar S, Barak V. Interleukin-1 activity in lesioned peripheral nerve. J Neuroimmunol 1992;39(1-2):75-80.

(179) Barak V, Kalickman I, Polliack A, Ginzburg M. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-hodgkin's lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 1992;7(5-6):431-438.

(180) Barak V, Mordel N, Zajicek G, Kalichman I, Treves AJ, Laufer N. The correlation between interleukin 2 and soluble interleukin 2 receptors to oestradiol, progesterone and testosterone levels in periovulatory follicles of in-vitro fertilization patients. Hum Reprod 1992;7(7):926-929.

(181) Barak V, Yanai P, Treves AJ, Roisman I, Simon A, Laufer N. Interleukin-1: Local production and modulation of human granulosa luteal cells steroidogenesis. Fertil Steril 1992;58(4):719-725.

(182) Barak V, Mordel N, Holzer H, Zajicek G, Treves AJ, Laufer N. The correlation of interleukin 1 and tumour necrosis factor to oestradiol, progesterone and testosterone levels in periovulatory follicular fluid of in-vitro fertilization patients. Hum Reprod 1992;7(4):462-464.

(183) Peled T, Rigel M, Peritt D, Fibach E, Treves AJ, Barak V. Effect of M20 interleukin-1 inhibitor on normal and leukemic human myeloid progenitors. Blood 1992;79(5):1172-1177.

(184) Mordel N, Anteby SO, Zajicek G, Roisman I, Treves A, Barak V. CA-125 is present in significant concentrations in periovulatory follicles of in vitro fertilization patients. Fertil Steril 1992;57(2):377-380.

(185) Gofrit O, Pode D, Gez E, Pfau A, Roizman I, Lifshitz Y, et al. Prostatic specific antigen for detection and monitoring of prostatic cancer. Harefuah 1992;122(6):345-"348, 408".

(186) Kalinkovich A, Engelmann H, Harpaz N, Burstein R, Barak V, Kalickman I, et al. Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol 1992;89(3):351-355.

(187) Roisman I, Barak V, Robinson E, Okon E, Livni N, Manny J, et al. Breast malignancies in adolescents in Israel (1967-1989). BREAST DIS 1992;5(3):149-168.

(188) Isacson R, Kedar E, Barak V, Gazit Z, Yurim O, Kalichman I, et al. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with decarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response. Immunol Lett 1992;33(2):127-134.

(189) Barak V, Peritt D, Flechner I, Yanai P, Halperin T, Treves AJ, et al. The specific IL-1 inhibitor from the human M20 cell line is distinct from the IL-1 receptor antagonist. Lymphokine Cytokine Res 1991;10(6):437-442.

(190) Roisman I, Gimmon Z, Barak V, Shoshani O, Lifshitz I, Barzilai M, et al. Breast developmental disorders and masses in childhood and adolescence. Harefuah 1991;121(11):463-468.

(191) Roisman I, Barak V, Okon E, Manny J, Durst AL. Benign cystosarcoma phyllodes of breast in an adolescent female. Breast Dis 1991;4(4):299-305.

(192) Friedman G, Barak V, Chajek-Shaul T, Etienne J, Treves AJ, Stein O, et al. Recombinant human interleukin-1 suppresses lipoprotein lipase activity, but not expression of lipoprotein lipase mRNA in mesenchymal rat heart cell cultures. Biochim Biophys Acta Gene Struct Expr 1991;1089(1):83-87.

(193) Roisman I, Barak V, Okon E, Sherman Y, Libson E, Durst AL. Adenolipoma of breast. Breast Dis 1991;4(2):153-159.

(194) Roisman I, Gimmon Z, Barak V, Durst AL. Appropriate diagnostic steps for proper clinical evaluation of breast lesions in the community. Harefuah 1991;120(5):266-270.

(195) Roisman I, Gimon Z, Barak V, Manny J. Clinical applicability of intraperitoneal administration of nutrients and drugs. Harefuah 1991;120(2):76-80.

(196) Mandelbaum-Shavit F, Barak V, Saheb-Tamimi K, Grossowicz N. Susceptibility of Legionella pneumophila grown extracellularly and in human monocytes to indole-3-propionic acid. Antimicrob Agents Chemother 1991;35(12):2526-2530.

(197) Gez E, Strauss N, Catane R, Roisman I, Barak V. The correlation between tumor response, serum prostatic-specific antigen and prostatic acid phosphatase in prostatic carcinoma patients receiving hormonetherapy. J TUMOR MARKER ONCOL 1991;6(1):45-52.

(198) Meirow D, Anteby SO, Ehrenfeld M, Barak V, Pras M. Serum CA-125 in familial mediterranean fever peritonitis. J TUMOR MARKER ONCOL 1991;6(1):31-37.

(199) Roisman I, Barak V, Manny J, Libson E, Wygoda M, Neuman A, et al. Fat necrosis below musculocutaneous flap mimicking carcinoma of breast. Ann Plast Surg 1991;26(5):479-482.

(200) Ben‐Ishay Z, Barak V, Shoshan S, Prindull G. Bone marrow stromal elements in murine leukemia: Decreased CSF‐producing fibroblasts and normal IL‐1 expression by macrophages. Eur J Haematol 1990;45(4):203-208.

(201) Roizman I, Gimon Z, Barak V. Breast cancer and pregnancy. Harefuah 1989;117(12):441-445.

(202) Roisman I, Gimon Z, Barak V. Male breast cancer. Harefuah 1989;117(3-4):68-74.

(203) Ovadia H, Abramsky O, Barak V, Conforti N, Saphier D, Weidenfeld J. Effect of interleukin-1 on adrenocortical activity in intact and hypothalamic deafferentated male rats. Exp Brain Res 1989;76(1):246-249.

(204) Roisman I, Barak V, Fields S, Bloom R, Okon E, Manny J. Solitary nonparasitic cyst of the liver: A rare cause of abdominal distension. Am J Gastroenterol 1989;84(9):1095-1099.

(205) Barak V, Carlin D, Sulkes A, Treves A, Biran S. CA15-3 serum levels in breast cancer and other malignancies. Correlation with clinical course. Isr J Med Sci 1988;24(9-10):623-627.

(206) Polliack A, Leizerowitz R, Barak V, Treves AJ, Gazitt Y. Effects of retinoic acid and phorbol ester on lymphocytes and monocytes in B-lymphocytic leukemia. Isr J Med Sci 1988;24(9-10):522-532.

(207) Barak V, Biran S, Halimi M, Treves AJ. The effect of estradiol on human myelomonocytic cells. II. Mechanism of enhancing activity of colony formation. J Reprod Immunol 1986;9(4):355-363.

(208) Treves AJ, Barak V, Halperin M, Biran S, Leizerowitz R, Polliack A. In vitro differentiation and establishment of cell lines derived from human myelomonocytic leukemia cells. Immunol Lett 1986;12(4):225-230.

(209) Barak V, Yamin M, Braun S, Halperin M, Biran S, Milner Y, et al. Detection of different interleukin-1 activities in human monocytes and monocytic cell lines. J Biol Response Modif 1986;5(4):362-375.

(210) Barak V, Treves AJ, Yanai P, Halperin M, Wasserman D, Biran S, et al. Interleukin 1 inhibitory activity secreted by a human myelomonocytic cell line (M20). Eur J Immunol 1986;16(11):1449-1452.

(211) Maoz H, Polliack A, Barak V, Yatziv S, Biran S, Giloh H, et al. Parameters affecting the in vitro maturation of human monocytes to macrophages. Int J Cell Cloning 1986;4(3):167-185.

(212) Treves AJ, Halperin M, Barak V, Bar-Tana R, Halimi M, Fibach E, et al. A new myelomonoblastic cell line (M20): Analysis of properties, differentiation, and comparison with other established lines of similar origin. Exp Hematol 1985;13(4):281-288.

(213) Maoz H, Kaiser N, Halimi M, Barak V, Haimovitz A, Weinstein D, et al. The effect of estradiol on human myelomonocytic cells. 1. Enhancement of colony formation. J Reprod Immunol 1985;7(4):325-335.

(214) Treves AJ, Fuks Z, Voss R, Tal T, Barak V, Konijn AM, et al. Establishment of cell lines from somatic cell hybrids between human monocytes and mouse myeloma cells. J Immunol 1984;132(2):690-694.

(215) Barak V, Fuks Z, Galilli N, Treves AJ. Selection and continuous growth of antigen‐specific human T cells by antigen‐treated monocytes. Eur J Immunol 1983;13(11):952-956.

(216) Treves AJ, Barak V, Tal T, Fuks Z. Constitutive secretion of interleukin 1 by human monocytes. Eur J Immunol 1983;13(8):647-651.

(217) Treves AJ, Tal T, Barak V, Fuks Z. Antigen presentation and regulatory functions of human monocytes in the in vitro response of lymphocytes against purified protein derivative of tuberculin (PPD). Eur J Immunol 1981;11(6):487-492.

(218) Treves AJ, Barak V, Fuks Z. Characterization of human lymphocytes which proliferate “spontaneously” in vitro. Eur J Immunol 1980;10(11):883-887.

(219) Treves AJ, Barak V, Fuks Z. In vitro proliferation of macrophage depleted human peripheral blood lymphocytes. Clin Exp Immunol 1979;38(3):531-538.